Insider Trading Alert - Express And 4 Others Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Sept. 26, 2013, 73 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $200.03 to $367,425,000.00.

Highlighted Stocks Traded by Insiders:

Express (EXPR) - FREE Research Report

Campbell Colin who is EVP - Sourcing and Production at Express sold 13,200 shares at $24.00 on Sept. 26, 2013. Following this transaction, the EVP - Sourcing and Production owned 164,694 shares meaning that the stake was reduced by 7.42% with the 13,200 share transaction.

Rafferty John J who is EVP - Planning and Allocation at Express sold 11,000 shares at $24.00 on Sept. 26, 2013. Following this transaction, the EVP - Planning and Allocation owned 142,325 shares meaning that the stake was reduced by 7.17% with the 11,000 share transaction.

Tilson Douglas H who is EVP - Real Estate at Express sold 9,398 shares at $24.00 on Sept. 26, 2013. Following this transaction, the EVP - Real Estate owned 112,573 shares meaning that the stake was reduced by 7.71% with the 9,398 share transaction.

The shares most recently traded at $23.94, down $0.06, or 0.25% since the insider transaction. Historical insider transactions for Express go as follows:

  • 4-Week # shares sold: 66,637
  • 12-Week # shares sold: 147,507
  • 24-Week # shares sold: 437,516

The average volume for Express has been 1.1 million shares per day over the past 30 days. Express has a market cap of $2.0 billion and is part of the services sector and retail industry. Shares are up 56.66% year to date as of the close of trading on Thursday.

Express, Inc. operates as a specialty apparel and accessory retailer primarily in the United States. Its stores provide apparel and accessories for women and men between 20 and 30 years old across various aspects of the lifestyles comprising work, casual, jeanswear, and going-out occasions. The company has a P/E ratio of 15.5. Currently there are 8 analysts that rate Express a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXPR - FREE

TheStreet Quant Ratings rates Express as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, good cash flow from operations and growth in earnings per share. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Express Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Alexandria Real Estate Equities (ARE) - FREE Research Report

Shigenaga Dean A who is Chief Financial Officer at Alexandria Real Estate Equities sold 5,000 shares at $65.37 on Sept. 26, 2013. Following this transaction, the Chief Financial Officer owned 55,599 shares meaning that the stake was reduced by 8.25% with the 5,000 share transaction.

The shares most recently traded at $64.60, down $0.77, or 1.19% since the insider transaction. Historical insider transactions for Alexandria Real Estate Equities go as follows:

  • 4-Week # shares sold: 12,000
  • 12-Week # shares sold: 14,000
  • 24-Week # shares sold: 25,250

The average volume for Alexandria Real Estate Equities has been 436,200 shares per day over the past 30 days. Alexandria Real Estate Equities has a market cap of $4.7 billion and is part of the financial sector and real estate industry. Shares are down 5.6% year to date as of the close of trading on Thursday.

Alexandria Real Estate Equities, Inc., a real estate investment trust (REIT), engages in the ownership, operation, management, development, acquisition, and redevelopment of properties for the life sciences industry. The stock currently has a dividend yield of 4.16%. The company has a P/E ratio of 48.8. Currently there are 4 analysts that rate Alexandria Real Estate Equities a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARE - FREE

TheStreet Quant Ratings rates Alexandria Real Estate Equities as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Alexandria Real Estate Equities Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Skechers USA (SKX) - FREE Research Report

Paccione Phillip who is General Counsel & Secretary at Skechers USA sold 3,400 shares at $30.00 on Sept. 26, 2013. Following this transaction, the General Counsel & Secretary owned 6,988 shares meaning that the stake was reduced by 32.73% with the 3,400 share transaction.

The shares most recently traded at $30.30, up $0.30, or 0.99% since the insider transaction. Historical insider transactions for Skechers USA go as follows:

  • 4-Week # shares sold: 2,250
  • 12-Week # shares sold: 27,250
  • 24-Week # shares sold: 27,250

The average volume for Skechers USA has been 611,700 shares per day over the past 30 days. Skechers USA has a market cap of $1.1 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 57.19% year to date as of the close of trading on Thursday.

Skechers U.S.A., Inc. engages in the design, development, marketing, and distribution of footwear for men, women, and children. It operates through four segments: Domestic Wholesale Sales, International Wholesale Sales, Retail Sales, and E-commerce Sales. The company has a P/E ratio of 51.0. Currently there are 4 analysts that rate Skechers USA a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SKX - FREE

TheStreet Quant Ratings rates Skechers USA as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Skechers USA Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Vertex Pharmaceuticals (VRTX) - FREE Research Report

Sachs Bruce I who is Director at Vertex Pharmaceuticals sold 8,300 shares at $74.97 on Sept. 26, 2013. Following this transaction, the Director owned 71,410 shares meaning that the stake was reduced by 10.41% with the 8,300 share transaction.

The shares most recently traded at $76.21, up $1.24, or 1.63% since the insider transaction. Historical insider transactions for Vertex Pharmaceuticals go as follows:

  • 4-Week # shares sold: 8,300
  • 12-Week # shares sold: 22,141
  • 24-Week # shares sold: 113,861

The average volume for Vertex Pharmaceuticals has been 2.2 million shares per day over the past 30 days. Vertex Pharmaceuticals has a market cap of $17.4 billion and is part of the health care sector and drugs industry. Shares are up 77.88% year to date as of the close of trading on Thursday.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Currently there are 12 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRTX - FREE

TheStreet Quant Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Vertex Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Kroger (KR) - FREE Research Report

Marmer Lynn who is Group Vice President at Kroger sold 3,675 shares at $40.80 on Sept. 26, 2013. Following this transaction, the Group Vice President owned 37,524 shares meaning that the stake was reduced by 8.92% with the 3,675 share transaction.

The shares most recently traded at $40.57, down $0.23, or 0.57% since the insider transaction. Historical insider transactions for Kroger go as follows:

  • 12-Week # shares sold: 52,009
  • 24-Week # shares sold: 52,009

The average volume for Kroger has been 3.9 million shares per day over the past 30 days. Kroger has a market cap of $21.2 billion and is part of the services sector and retail industry. Shares are up 56.99% year to date as of the close of trading on Thursday.

The Kroger Co., together with its subsidiaries, operates as a retailer in the United States. The company also manufactures and processes food for sale in its supermarkets. It operates retail food and drug stores, multi-department stores, jewelry stores, and convenience stores. The stock currently has a dividend yield of 1.62%. The company has a P/E ratio of 13.6. Currently there are 6 analysts that rate Kroger a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KR - FREE

TheStreet Quant Ratings rates Kroger as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, good cash flow from operations, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Kroger Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers